Literature DB >> 8110878

Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood.

D Menzel1, M Levi, G Dooijewaard, M Peters, J W ten Cate.   

Abstract

Thrombotic obstruction of glomerular capillaries causes acute renal failure in patients with hemolytic-uremic syndrome (HUS). Recanalization of occluded vessels normally occurs by activation of the endogenous fibrinolytic system, mediated by plasminogen activators, which are stored and synthesized in the endothelial cells. However, endothelial injury is considered the primary event in the pathogenesis of HUS, and this may result in impaired fibrinolysis. In five children with HUS we performed a prospective study of plasminogen activator activity and two plasminogen activator antigens: tissue-type plasminogen activator and urokinase-type plasminogen activator before and after intravenous desmopressin. Plasminogen activator inhibitor type-1 antigen was also studied. In the acute stage of HUS plasminogen activating activity was low, in spite of elevated levels of total plasminogen activator antigens. This decrease of plasminogen activating activity was due to high levels of the plasminogen activator inhibitor. Improvement of fibrinolysis paralleled recovery from HUS. We conclude that decreased fibrinolysis is an important pathophysiologic feature of HUS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8110878     DOI: 10.1007/bf01695919

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  32 in total

1.  Quantitation of urokinase antigen in plasma and culture media by use of an ELISA.

Authors:  D J Binnema; J J van Iersel; G Dooijewaard
Journal:  Thromb Res       Date:  1986-09-01       Impact factor: 3.944

2.  Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

Authors:  J D Cash; A M Gader; J da Costa
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

3.  Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin.

Authors:  S Kasai; H Arimura; M Nishida; T Suyama
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

4.  Haemolytic uraemic syndrome.

Authors:  M Levin; J M Barratt
Journal:  Arch Dis Child       Date:  1984-05       Impact factor: 3.791

5.  Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.

Authors:  V W van Hinsbergh; E A van den Berg; W Fiers; G Dooijewaard
Journal:  Blood       Date:  1990-05-15       Impact factor: 22.113

6.  Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.

Authors:  N L Kobrinsky; J J Doyle; E D Israels; J S Winter; M S Cheang; R D Walker; A J Bishop
Journal:  Lancet       Date:  1985-06-08       Impact factor: 79.321

7.  DDAVP induces systemic release of urokinase-type plasminogen activator.

Authors:  M Levi; J W ten Cate; G Dooijewaard; A Sturk; E J Brommer; G Agnelli
Journal:  Thromb Haemost       Date:  1989-09-29       Impact factor: 5.249

8.  Fibrinolytic activity in end-stage renal disease.

Authors:  S Y Hong; D H Yang
Journal:  Nephron       Date:  1993       Impact factor: 2.847

9.  Plasma inhibitor of glomerular fibrinolysis in the hemolytic-uremic syndrome.

Authors:  J M Bergstein; U Kuederli; N U Bang
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

10.  Fibrinolytic response to tumor necrosis factor in healthy subjects.

Authors:  T van der Poll; M Levi; H R Büller; S J van Deventer; J P de Boer; C E Hack; J W ten Cate
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

View more
  3 in total

1.  Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome.

Authors:  Anne-lie Ståhl; Majlis Svensson; Matthias Mörgelin; Catharina Svanborg; Phillip I Tarr; Jody C Mooney; Sandra L Watkins; Roger Johnson; Diana Karpman
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

Review 2.  Hemostatic complications in renal disorders of the young.

Authors:  M Andrew; L A Brooker
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

3.  EspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot Lysis.

Authors:  Kevin H M Kuo; Shekeb Khan; Margaret L Rand; Hira S Mian; Elena Brnjac; Linda E Sandercock; Indira Akula; Jean-Philippe Julien; Emil F Pai; Alden E Chesney
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.